Mylan Inc (MYL) 72.40 $MYL Will Teva Manage To Complete

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:36 PM

Mylan Inc (MYL) 72.40 $MYL

Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - 1 hr 51 mins ago

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09)

Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - 2 hrs 8 mins ago
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)

Concerns About Soaring Generic Prices Could Present Teva With Ultimate Challenge
EP Vantage - Seeking Alpha - Wed Apr 22, 11:31AM CDT
That Teva (NYSE: TEVA ) would declare its interest in Mylan (NASDAQ: MYL ) was a foregone conclusion. The consummation of any such deal is far from certain. An agreement on price would probably get investors in both camps on board, but these are...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)

Mylan preparing new bid for Perrigo
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:47AM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan
at The Street - Wed Apr 22, 8:46AM CDT
Teva has a path to complete the deal.
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Critical Alerts For Celgene, Rambus, Mylan, Amgen and Zoetis Released By InvestorsObserver
PR Newswire - Wed Apr 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, RMBS, MYL, AMGN and ZTS.
ZTS: 47.03 (-0.51), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), RMBS: 14.40 (+0.22), CELG: 115.54 (+0.72)

Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:00AM CDT
Perrigo Company's third-quarter fiscal 2015 earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.
BIIB: 423.57 (+1.46), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
ENZN: 1.70 (+0.20), HLF: 46.63 (-0.13), VSI: 44.50 (+5.54), GNC: 47.56 (+1.60), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
Business Wire - Wed Apr 22, 7:30AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva's proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion.
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Upgrade Alert for Mylan (MYL)
Comtex SmarTrend(R) - Wed Apr 22, 7:11AM CDT
Mylan (NASDAQ:MYL) was upgraded from Underperform to Market Perform at BMO Capital today. The stock closed yesterday at $74.07 on volume of 42.3 million shares, above average daily volume of 10.4 million. Based on a current price of $74.07, Mylan is currently 15.7% above its average consensus analyst price target of $62.44. The stock should find initial support at its 50-day moving average (MA) of $60.20 and further support at its 200-day MA of $53.86.
MYL: 72.40 (-1.67)

Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)

Wall Street Breakfast: China Shares Extend Bull Run
Wall Street Breakfast - at Seeking Alpha - Wed Apr 22, 5:30AM CDT

PRGO: 201.50 (+8.68), BX: 41.76 (+0.04), SNE: 32.35 (+1.47), GOOG: 539.36 (+5.39), NOV: 53.93 (+0.80), YHOO: 43.97 (-0.52), SPY: 210.63 (+1.03), RIG: 16.85 (-0.18), S: 5.08 (+0.10), CMG: 641.23 (-51.29), FOXA: 34.04 (+0.09), GOOGL: 549.18 (+6.26), TMUS: 34.09 (+0.74), TWC: 149.64 (-2.36), MYL: 72.40 (-1.67), DIS: 107.94 (+0.26), PXD: 172.93 (-0.64), QQQ: 108.65 (+0.59), ARMH: 54.07 (+0.47), TEVA: 63.01 (-1.15), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), EPD: 33.35 (-0.29)

Reuters: Top Mylan shareholders seek deal with Teva
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 2:01AM CDT

MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Update - Perrigo's Rejection Of Offer Gives Mylan 5 Strategy Options
Jordan Flannery - at Seeking Alpha - Tue Apr 21, 11:01PM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Perrigo unanimously rejects Mylan bid
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:53PM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67)

Watch for Mylan to Potentially Pullback After Gaining 8.85% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 3:45PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $72.99 to a high of $74.90. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $72.16 on volume of 42.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 72.40 (-1.67)

Look for Shares of Mylan to Potentially Pullback after Yesterday's 8.85% Rise
Comtex SmarTrend(R) - Tue Apr 21, 3:44PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $72.99 to a high of $74.90. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $72.16 on volume of 42.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 72.40 (-1.67)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

wagamama Spruces Up U.S. Market with mamago Launch

What's Cooking at wagamama with mamago? Here comes wagamama, striding into the American dining scene with that familiar bold Pan-Asian flair, now offering more than just a seat at their tables. The fresh move to a direct-to-door model dubbed ‘mamago’ ushers in an era where their signature dishes don't just seduce your taste buds at their restaurants. Nope, they are...

Modular Building Boom Shakes Up Asian Construction

Building the Future, One Module at a Time What's ticking in the world of construction? Modular buildings, my friends. They're generating buzz at the Fourth Linyi Mall International Buyers Conference held last week, and for good reasons. If you're not following, China is rolling out prefabricated houses like they're the next big thing since sliced bread, leaving buyers in...

BioMarin Strikes Deal for New Fabry Disease Therapy

BioMarin's Latest Moves in Rare Disease Therapies Now here's a plot twist in the biotechnology landscape. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) just did what they do best—snagging rights to a promising enzyme therapy aimed at turning the tide for Fabry disease. In a deal that spoke volumes about their intentions, BioMarin is forking over a cool $70 million upfront...

Freddy's Partners with Convoy of Hope for Charity Drive

Freddy’s and Convoy of Hope: A Sweet Collaboration Plunging headfirst into charitable waters, Freddy's Frozen Custard & Steakburgers has announced a partnership with Convoy of Hope for a cause-centric month. From November 1 to December 1, Freddy's is urging patrons to chip in for the broader good. It’s simple – round up your in-store or drive-thru bill to the...

Stellar's New VP Aims to Bridge Space and Tech

Ain't every day you see a heavyweight like Rister stepping into a new role, especially when he's packing thirty years of experience in his tool belt. Bradley J. Rister, now the Vice President of Commercial Solutions Sector at Stellar Solutions, isn't just taking over a desk job. Nope, he's got a pivotal role in gearing up the company’s commercial tech for national...

CallRail's New Insight Tool: Navigating the Competitive Landscape

How CallRail's New Feature Changes the Game Ever sit in a boardroom meeting and wonder what your lead numbers really mean? CallRail just dropped a new feature that could change that. This AI-powered platform is now decking its 225,000 businesses with market insights to not just know their numbers but to understand how they stack up against their competition in the same...

TXNM Energy's Q3 2026 Hits Hard Amid Heat and M&A

TXNM Energy: A Strong Q3 2026 Amid Acquisition Waves Every so often, a company struts into earnings season and lays all its cards on the table. TXNM Energy just did that for Q3 2026, showing some robust numbers and setting tongues wagging on Wall Street. With GAAP earnings per diluted share shooting up to $1.50 from $1.22 the previous year, it's clear the power play is...

Prenatal Omega-3s and Childhood Brainpower: A Study

Omega-3s and Child Development: Why the Buzz? Alright, let's dig into a study that's grabbing attention: it's all about how those little omega-3 fatty acids, the kind found in walnuts and fish, might just be crafting our kids into brainiacs. The latest research published in the European Journal of Epidemiology connects these fatty acids to cognitive prowess from childhood...

Geolava, Vaidio, Sensoneo Triumph in Texas Pitch Contest

North Texas Lights the Innovation Torch Big moves are happening in North Texas, with a pitch competition that's more than just smoke and mirrors. We're talking about an arena where regional challenges meet cutting-edge solutions, and out of a global mix, Geolava, Vaidio, and Sensoneo snagged the 2026 North Texas Connected Innovation Pitch Contest crown. It's high stakes...

Keller Joins JC Behavioral Health Council, RCA Shines

RCA's Role in Behavioral Health Standards Kendall Keller just grabbed a prime seat at a table that could shape the future of behavioral healthcare in the U.S. Appointed to the Joint Commission’s (JC) Behavioral Health Care & Human Services Advisory Council, Keller isn’t lounging around. Here’s someone with 18 years under her belt, tasked with steering the ship for...